COVID-19: Vaccines and Therapeutics
The White House announced a $10 billion investment in promoting public confidence in COVID-19 vaccines, particularly among the hardest-hit and highest-risk communities.
Throughout the pandemic, innovative partnerships have helped hospitals and health systems ensure ongoing care for patients, health care workers and their communities. Here are some of the success stories that have shone brightly at every phase of this public health emergency. Plus, there鈥檚 an鈥
Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized monoclonal antibodies, the U.S. government, in coordination with Eli Lilly, will stop the distribution of bamlanivimab alone starting today, the Department of Health and Human鈥
On this AHA Advancing Health podcast, Germaine Smith-Baugh, president and CEO of the Urban League of Broward County in Ft. Lauderdale, Fla., talks about combating the COVID-19 pandemic through testing, vaccinations and education within the community, which include people hardest hit by the pandemic鈥
Join the AHA March 30 at 12 p.m. ET to hear how Atrium Health and American Airlines came together to 鈥済et shots in arms鈥 through mass vaccination events in Charlotte, N.C. Webinar speakers will discuss the planning, partnerships and support required to hold these events.
The AHA today released a new episode of PowerPlay, the on-demand video series that connects AHA members to major players in policy, politics and science. The episode features a conversation between AHA鈥檚 Michelle Hood, executive vice president and chief operating officer, and Bechara Choucair, M.D鈥
Featuring Dr. Bechara Choucair, Vaccinations Coordinator for the White House COVID Response Team. On March 22, Dr. Choucair spoke with AHA鈥檚 Michelle Hood, executive vice president and chief operating officer about the administration鈥檚 plans to utilize hospitals and health systems in vaccination鈥
AstraZeneca said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients.
The Department of Health and Human Services (HHS) March 19 updated its guidance to hospitals on the reporting of COVID-19-related data.
The Food and Drug Administration yesterday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy.